Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glasdegib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glasdegib SCHEMBL18171548 | 1.00 | USP30 (0.41) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18171549 | 1.00 | USP30 (0.41) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL27100349 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL29359708 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL22104131 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL24503991 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL18184932 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL2068480 | 0.95 | EPHX1 (0.45) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL29362720 | 0.94 | EPHX1 (0.44) | USP30EPHX1NPC1RAB9APOLB | |
| Glasdegib SCHEMBL2068016 | 0.94 | EPHX1 (0.44) | USP30EPHX1NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4014047-B1 | OGDH INHIBITORS FOR USE IN THE TREATMENT OF CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-05-22 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4504784-A1 | TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS TARGETING NOVEL TUMOR SPECIFIC ANTIGENS | Altheia Science S.r.l. (IT) | 2025-02-12 | — | — | EP | claimed |
| WO-2024263573-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| WO-2022214499-A9 | DIAGNOSIS AND TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS USING NOVEL TUMOR SPECIFIC ANTIGENS | ALTHEIA SCIENCE S.R.L. (IT) | 2023-01-05 | — | — | WO | claimed |
| EP-4110351-A1 | LIQUID BIOPSY YIELD ENHANCEMENT | Singhal, Seema (US) | 2023-01-04 | — | — | EP | claimed |
| EP-4097093-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-12-07 | — | — | EP | claimed |
| CN-115379837-A | Transdermal formulations for drug administration | 黛芙生物科学公司 | 2022-11-22 | — | — | CN | claimed |
| WO-2022214499-A2 | DIAGNOSIS AND TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS USING NOVEL TUMOR SPECIFIC ANTIGENSCROSS-REFERENCE TO RELATED APPLICATIONS | ALTHEIA SCIENCE S.R.L. (IT) | 2022-10-13 | — | — | WO | claimed |
| US-20220280538-A1 | METHODS OF TREATING P53 MUTANT CANCERS USING OGDH INHIBITORS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-09-08 | — | — | US | claimed |
| WO-2022175595-A1 | LINKER-PAYLOADS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2022-08-25 | — | — | WO | claimed |
| WO-2022159624-A1 | LIQUID BIOPSY YIELD ENHANCEMENT | SINGHAL SEEMA (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022155352-A1 | TRANSDERMAL PENETRANT FORMULATIONS FOR ADMINISTRATION OF MEDICAMENTS | DYVE BIOSCIENCES, INC. (US) | 2022-07-21 | — | — | WO | claimed |
| EP-4014047-A1 | METHODS OF TREATING P53 MUTANT CANCERS USING OGDH INHIBITORS CROSS-REFERENCE TO RELATED APPLICATIONS | Memorial Sloan Kettering Cancer Center (US) | 2022-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161478-A1 | LINKER PAYLOADS AND CONJUGATES THEREOF | PAICS, CD47, CD44 | USP30 2339/4885EPHX1 3079/4885NPC1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.